
Friday, November 14, 2025 | 8am PDT/11am EDT
Obesity remains a critical global health threat, affecting over one billion people worldwide and exacerbating risks for type 2 diabetes, cardiovascular diseases, and fatty liver disease. The pharmaceutical landscape is witnessing rapid transformation through novel oral GLP-1 agents, long-acting injectables, and multi-target therapies that are redefining treatment possibilities.
At the preclinical stage, BioDuro's Diet-Induced Obesity (DIO) rodent models, enhanced with high-resolution phenotyping tools, create a crucial translational bridge to accelerate weight loss drug development.
Key Topics:
Whether advancing weight loss programs or exploring novel targets, this webinar delivers practical insights to support your drug development initiatives.
